Arca
Skip to content
Tools
Tools

Neurotrophic tyrosine kinase receptor

Family in Homo sapiens that 8 drugs act on.

  • Drugs that act on it: 8
  • Approved: 3
  • In phases 1 to 3: 5
  • Sponsors: 6
  • Genes: 3

Who is on it, and how far along

Every drug ChEMBL records acting on NTRK1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 6
  • Protein or peptide 1
  • Other 1

Approved3

  • Entrectinib
  • Larotrectinib
  • Cenegermin

Phase 30

    Phase 23

    • Taletrectinib
    • Altiratinib
    • Selitrectinib

    Phase 12

    • AZD-6918
    • CEP-2563

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 7 of 8 act as: Neurotrophic tyrosine kinase receptor inhibitor; the rest name their own mechanism.
    EntrectinibApprovedRocheSmall moleculeInhibitor26
    LarotrectinibApprovedBayerSmall moleculeInhibitor20
    CenegerminApprovedDompé FarmaceuticiProtein or peptideAgonistNeurotrophic tyrosine kinase receptor agonist4
    TaletrectinibPhase 2Nuvation BioSmall moleculeInhibitor6
    AltiratinibPhase 2Ono PharmaceuticalSmall moleculeInhibitor0
    SelitrectinibPhase 2BayerSmall moleculeInhibitor0
    AZD-6918Phase 1AstraZeneca PharmaceuticalsOtherInhibitor0
    CEP-2563Phase 1—Small moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 24 in all, from ClinicalTrials.gov.
    Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric GliomaEntrectinibPhase 2Not yet recruitingSt. Jude Children's Research HospitalNov 4, 2026
    Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot StudyLarotrectinibEarly phase 1Not yet recruitingOlivia Newton-John Cancer Research InstituteOct 30, 2026
    A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor MonotherapyLarotrectinibPhase 1 / Phase 2Not yet recruitingM.D. Anderson Cancer CenterSep 28, 2026
    Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver MutationsEntrectinibPhase 2Not yet recruitingShanghai Zhongshan HospitalSep 21, 2026
    Molecularly Tailored Therapy in Advanced Pancreatic CancerLarotrectinibPhase 2Not yet recruitingHerlev HospitalSep 3, 2026
    Study on the Effect of Famotidine on Pharmacokinetics of TaletrectinibTaletrectinibPhase 1Not yet recruitingNuvation Bio Inc.Aug 3, 2026
    An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCEDCenegerminPhase 3RecruitingDompé Farmaceutici S.p.AApr 9, 2026
    Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)CenegerminPhase 3RecruitingDompé Farmaceutici S.p.AMar 6, 2026
    Study on the Mechanism of Acquired Resistance of EntrectinibEntrectinib—RecruitingFudan UniversitySep 30, 2025
    Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib ProgressionEntrectinib, Taletrectinib—Not yet recruitingInnovent Biologics (Suzhou) Co. Ltd.Sep 30, 2025
    Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)TaletrectinibPhase 3RecruitingNuvation Bio Inc.Sep 4, 2025
    Corneal Neurotization vs. Cenergermin for Neurotrophic Keratitis: A Pilot StudyCenegerminNot applicableNot yet recruitingLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sJul 18, 2025
    Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyLarotrectinibPhase 4Not yet recruitingFujian Medical UniversityJun 8, 2025
    Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain MetastasesTaletrectinib—RecruitingInnovent Biologics (Suzhou) Co. Ltd.Jun 6, 2025
    DOMPE -MT Neurotrophic KeratitisCenegerminPhase 4Active, not recruitingToyos ClinicApr 27, 2025
    Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLCEntrectinib—Not yet recruitingNational Cancer Center, ChinaNov 19, 2024
    Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSEntrectinibPhase 2Not yet recruitingPeking University Shenzhen HospitalNov 18, 2024
    Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.LarotrectinibPhase 2RecruitingSun Yat-sen UniversityAug 21, 2024
    A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer PatientsTaletrectinibPhase 3RecruitingNuvation Bio Inc.Aug 21, 2024
    Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS TumorsEntrectinibPhase 2RecruitingSt. Jude Children's Research HospitalJul 30, 2024
    Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerEntrectinib, LarotrectinibPhase 2RecruitingWest China HospitalJul 1, 2024
    Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)LarotrectinibPhase 2Active, not recruitingNational Cancer Institute (NCI)Apr 30, 2024
    A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid CancerLarotrectinibPhase 4RecruitingFudan UniversityJan 8, 2024
    Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLCTaletrectinibPhase 2Active, not recruitingNuvation Bio Inc.Jun 9, 2021

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3559684, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.